Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, TRUTH, matthewverymuch
Search This Board:
Last Post: 12/18/2014 10:16:55 AM - Followers: 153 - Board type: Free - Posts Today: 0


 






Products


Probuphine®-This study is enrolling participants by invitation only.

Click For Link To ClinicalTrials.gov


*November 20, 2014 -  the study is 100% enrolled.
                                                                    * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For cnn.com Link 


Sponsor:

Braeburn Pharmaceuticals


ClinicalTrials.gov Identifier:
Information provided by (Responsible Party):
NCT02180659
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals









Probuphine Graphic

 

 

 

Continuous Drug Delivery Technology

 

The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

 



Fanapt® (iloperidone)

 

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.




Company Overview



Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

President
Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.

 



Board of Directors

 
 
  






 

Strategic Alliances


In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

 





Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at     sbhonsle@titanpharm.com

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TTNP
Current Price
Volume:
Bid Ask Day's Range
Wiki
TTNP News: Current Report Filing (8-k) 12/04/2014 12:24:57 PM
TTNP News: Quarterly Report (10-q) 11/13/2014 04:43:30 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:13:05 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:08:51 PM
TTNP News: Statement of Ownership (sc 13g) 10/10/2014 10:20:57 AM
PostSubject
#3684  Sticky Note ****Addicts DESPERATELY Waiting For A Lifesaver**** TRUTH 09/27/14 11:41:37 AM
#4042   Kinda wish someone from Titan/Braeburn had been at Doctor Detroit 12/18/14 10:16:55 AM
#4041   I find it ridiculous that 4th quarter cc matthewverymuch 12/17/14 04:40:10 PM
#4040   From Titan's S-1 Registration Statement: "We have agreed TRUTH 12/17/14 03:44:17 PM
#4039   Who required Titan to hold the shareholders meeting? Rentier 12/17/14 10:09:27 AM
#4038   We have no evidence that braeburn invested any matthewverymuch 12/16/14 10:15:13 PM
#4037   Think the reverse split verbiage was in there Rentier 12/16/14 01:45:58 PM
#4036   125 million authorized, with 109 million outstanding as Doctor Detroit 12/16/14 10:36:51 AM
#4035   Why would Sunil and Marc buy shares ahead Rentier 12/15/14 06:11:40 PM
#4034   I found it in the S-1 registration statement Doctor Detroit 12/15/14 03:51:20 PM
#4033   Hey truth...got your private message....did as you asked...if matthewverymuch 12/15/14 03:06:30 PM
#4032   Correct me if I'm wrong but that statement bluejacket6 12/15/14 03:03:51 PM
#4031   Shareholders Meeting Doctor Detroit 12/15/14 12:29:47 PM
#4030   Self-Help: Addicts Buying Suboxone On Street TRUTH 12/14/14 06:27:19 PM
#4029   Opioid Prescriber Monitoring May Increase Overdose Deaths TRUTH 12/14/14 04:57:47 PM
#4028   Historical Short Selling Data For TTNP TRUTH 12/12/14 11:51:22 PM
#4027   Doesn't stand for CAMurus? TRUTH 12/12/14 06:50:10 PM
#4026   Doesn't stand for CAMurus? matthewverymuch 12/12/14 06:15:23 PM
#4024   Could be something, perhaps not.. TRUTH 12/12/14 11:00:46 AM
#4023   if you don't mind me asking, what TRUTH 12/12/14 10:53:54 AM
#4022   Very interesting response, so I guess I'll(we) turks 12/12/14 10:38:26 AM
#4021   Thanks truth. Could be something, perhaps not.. at matthewverymuch 12/12/14 10:34:21 AM
#4020   **Response From Braeburn Pharmaceuticals** TRUTH 12/12/14 10:00:58 AM
#4019   Good to hear, Thanks TRUTH!! bluejacket6 12/11/14 04:21:51 PM
#4018   I just sent Titan an email inquiry,as phone TRUTH 12/11/14 04:18:56 PM
#4017   FYI.... I spoke with Braeburn this morning and all TRUTH 12/11/14 03:51:50 PM
#4016   Rent Love your insight always valuable and spot on!! bluejacket6 12/11/14 01:34:31 PM
#4015   Titan Website: TRUTH 12/10/14 10:14:34 PM
#4014   According to the delpor website TRUTH 12/10/14 09:57:14 PM
#4013   According to the delpor website, they are still matthewverymuch 12/10/14 09:20:15 PM
#4012   Whatever's going on,we will see soon enough. TRUTH 12/10/14 05:58:57 PM
#4011   You are not reading it correctly, Phase II Rentier 12/10/14 05:42:18 PM
#4010   Well I would but you see that link Rentier 12/10/14 05:40:47 PM
#4009   why isn't Delpor showing at phase III like TRUTH 12/10/14 05:39:54 PM
#4008   Check the SBIR site on the far right TRUTH 12/10/14 05:30:41 PM
#4007   No, because they are not ready to start Rentier 12/10/14 05:20:16 PM
#4006   That is all fine and good but why Rentier 12/10/14 05:15:50 PM
#4005   Don't you think that Braeburn would've announced that TRUTH 12/10/14 05:14:56 PM
#4004   If this were the case,why isn't Titan announcing TRUTH 12/10/14 05:10:20 PM
#4003   Do you have any news announcement linking Delpor Rentier 12/10/14 05:08:08 PM
#4002   You think that is the implant that Braeburn TRUTH 12/10/14 05:04:59 PM
#4001   I don't know but the Phase II trial Rentier 12/10/14 04:55:26 PM
#4000   You think that is the implant that Braeburn Rentier 12/10/14 04:51:05 PM
#3999   Could it have been one of the secondary matthewverymuch 12/10/14 02:46:39 PM
#3998   Funny, I looked up the CAM2038 Phase II Doctor Detroit 12/10/14 02:26:21 PM
#3997   wonder why they hooked up with braeburn TRUTH 12/10/14 01:43:29 PM
#3996   Yeah..4 trials at once..impressive. wonder why they hooked matthewverymuch 12/10/14 01:24:19 PM
#3995   Delpor is surely better funded than Titan is: TRUTH 12/10/14 01:20:32 PM
#3994   No problem. TRUTH 12/10/14 01:14:52 PM
#3993   Thanks matthewverymuch 12/10/14 01:11:41 PM
#3992   Where did they get the implant from? TRUTH 12/10/14 12:56:08 PM
PostSubject